Rationale and necessity for delivery of RRx-001, a Myc and CD47 antagonist, by intravenous blood mix

Scott Caroen,Bryan Oronsky,Corey Carter,Michelle Lybeck,Arnold Oronsky,Tony Reid

EXPERT OPINION ON DRUG DELIVERY（2020）

引用 6|浏览0

暂无评分

摘要

RRx-001, a dinitroazetidine-based small molecule in Phase 3 for small cell lung cancer (SCLC) and in a randomized trial for the treatment of COVID-19, is a first-in-class Myc inhibitor that also do...

查看译文

关键词

Oncology,intravenous infusion,small molecule,RRx-001,blood mix,CD47,PD-L1,MYC

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要